← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1 · 임상 갱신 필요 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV26행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyLimited DatastalePhase 2
protein analysis (protein analysis)
The Scientific and Technological R…·Chronic Myeloproliferative Disorde…
93 trials
Overview
Program
protein analysis
Overview
Company
The Scientific and Technological Research Council of Turkey
Overview
Modality
ANTIBODY
Overview
Target
Chronic Myeloproliferative Disorders
Overview
Indication
Chronic Myeloproliferative Disorders; Leukemia
Overview
Phase
PHASE_2
Overview
Status
DISCONTINUED
Overview
Content status
Limited Data
Overview
Data Confidence
Data Confidence · Low
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
MoA
Mechanism
target within the Kras signalling pathway
MoA
Biomarker
Biomarkers in Patients With Rheumatoid Arthritis but Normal ESR/CRP Receiving Biological/Targeted Synthetic D
PK/PD
Species
Mouse, Rat
PK/PD
Animal (cat.)
Human, Mouse, Rat, In vitro
PK/PD
Experiment
PD
Toxicology
Species
Mouse, Rat
Toxicology
Animal (cat.)
Human, Mouse, Rat, In vitro
Toxicology
Major finding
Exposure of dairy goat mammary epithelial cells to bis(2-ethylhexyl) phthalate induces oxidative stress and alters gene/protein expression, posing health risks.. The goat milk industry is expanding, yet the toxic effects of bis(2-ethylhexyl) phthalate (DEHP) on goat mammary glands remain understudied despite extensive in vivo research in mice and humans. This study used mammary epithelial cells to…
Clinical
Safety signal
Exposure of dairy goat mammary epithelial cells to bis(2-ethylhexyl) phthalate induces oxidative stress and alters gene/protein expression, posing health risks.. The goat milk industry is expanding, yet the toxic effects of bis(2-ethylhexyl) phthalate (DEHP) on goat mammary glands remain understudied despite extensive in vivo research in mice and humans. This study used mammary epithelial cells to…
Clinical
Reported PFS
0.263
Clinical
Reported OS
5.58
Clinical
Result source
ClinicalTrials.gov NCT00621686
Clinical
Program phase
PHASE_2
Clinical
Trial activity
No active/completed counts
Clinical
Trial ref
NCT00621686